Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| P21 (Cerebrolysin Analog) | TB-500 (Thymosin Beta-4) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 750 mcg-1 mg daily via intranasal administration or subcutaneous injection. | Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection. |
| Timing | Morning dosing preferred for cognitive effects. | No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical. |
| Cycle Duration | 4-8 week cycles with 4-week rest periods. | Loading phase: 4-6 weeks. Total cycle: 8-16 weeks. |
| Evidence Level | animal_plus_anecdotal | animal_plus_anecdotal |
P21 is a tetrapeptide (DGGL — Asp-Gly-Gly-Leu) derived from the most active region of ciliary neurotrophic factor (CNTF, residues 148-151), identified through reverse engineering of Cerebrolysin. An adamantylated glycine enhances BBB permeability and metabolic stability. P21 works through LIF/STAT3 pathway inhibition, BDNF/TrkB/CREB signaling enhancement, and restoration of synaptic proteins (synaptophysin, synapsin I) and glutamate receptors. It promotes neurogenesis and maturation of newborn neurons in the dentate gyrus.
Research indicates 750 mcg-1 mg daily via intranasal administration or subcutaneous injection.
Morning dosing preferred for cognitive effects.
4-8 week cycles with 4-week rest periods.
TB-500 is a synthetic fragment of Thymosin Beta-4, a 43-amino acid protein that sequesters G-actin monomers, preventing premature polymerization and facilitating cellular migration and morphological changes essential for wound healing. It upregulates actin to promote cell migration, proliferation, and differentiation of stem/progenitor cells at injury sites. TB-500 also enhances angiogenesis, reduces inflammation, and promotes tissue remodeling through increased re-epithelialization and vascular density.
Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection.
No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical.
Loading phase: 4-6 weeks. Total cycle: 8-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →